Showing results (131-140 of 161) with videos related to

Sort By:
Pageof 17
Reproductive Toxicology (Elmsford, N.Y.)|December 29, 1999
Effects of lactational administration of acrylamide on rat dams and offspringM A Friedman, R W Tyl, M C Marr, et al.
Cancer|January 1, 1981
Estrogen receptors in male breast cancer: clinical and pathologic correlationsM A Friedman, P G Hoffman, E M Dandolos, et al.
Annals of the Academy of Medicine, Singapore|April 1, 1980
Therapy of hepatocellular cancer with combined intrahepatic arterial chemotherapy and whole liver irradiationM A Friedman, P A Volberding, M J Cassidy, et al.
Journal of Consulting and Clinical Psychology|August 31, 2000
Comorbid psychopathology in binge eating disorder: relation to eating disorder severity at baseline and following treatmentD E Wilfley, M A Friedman, J Z Dounchis, et al.
Journal of Toxicology and Environmental Health|August 1, 1993
Neurotoxicity of glycidamide, an acrylamide metabolite, following intraperitoneal injections in ratsM B Abou-Donia, S M Ibrahim, J J Corcoran, et al.
The New England Journal of Medicine|November 30, 1995
The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06M C Christian, M S McCabe, E L Korn, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|August 1, 1983
Effect of dietary administration of the rubber curative trithiocyanuric acid to the ratF J Koschier, D R Brown, M A Friedman, et al.
Cancer Treatment Reports|November 1, 1979
Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group StudyM A Friedman, P A Volberding, M J Cassidy, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationD A Rinaldi, J G Kuhn, H A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.
Pageof 17